Leukemia. 2007 Jan;21(1):151-7. Epub 2006 Nov 9.

Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials.

Jagannath S, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Cowan JM, Anderson KC.

Source

Department of Medical Oncology, St Vincent's Comprehensive Cancer Center, New York, NY 10011-8202, USA. sjagannath@aptiumoncology.com

Abstract

In multiple myeloma, deletion of chromosome 13 (del(13)) is associated with poor prognosis regardless of treatment. This study analyzed the impact of del(13) status on response and survival following treatment with either bortezomib or high-dose dexamethasone in patients in the SUMMIT and APEX trials. Additionally, matched-pairs subset analyses were conducted of patients with and without del(13), balanced for age and International Staging System parameters. In both SUMMIT and APEX, prognosis appeared to be poorer in bortezomib-treated patients with del(13) compared with patients with no del(13) by metaphase cytogenetics. In the SUMMIT and APEX matched-pairs analysis, response and survival appeared comparable in bortezomib-treated patients with or without del(13) by metaphase cytogenetics. However, patients with del(13) receiving dexamethasone in APEX appeared to have markedly decreased survival compared with those without del(13) by metaphase cytogenetics. These matched-pairs analyses suggest that bortezomib may overcome some of the poor impact of del(13) as an independent prognostic factor. However, sample sizes were very small; these findings require confirmation from further studies.

PMID:: 17096017; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Supplemental Content

Related citations

Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. [Leukemia. 2007]
Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.
Sagaster V, Ludwig H, Kaufmann H, Odelga V, Zojer N, Ackermann J, Küenburg E, Wieser R, Zielinski C, Drach J. Leukemia. 2007 Jan; 21(1):164-8. Epub 2006 Nov 9.
An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era. [Am J Hematol. 2010]
An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
Tan D, Teoh G, Lau LC, Lim A, Lim TH, Yap KC, Premalatha P, Lao ZT, Wee N, Choo C, et al. Am J Hematol. 2010 Oct; 85(10):752-6.
Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). [J Clin Oncol. 2010]
Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).
Avet-Loiseau H, Leleu X, Roussel M, Moreau P, Guerin-Charbonnel C, Caillot D, Marit G, Benboubker L, Voillat L, Mathiot C, et al. J Clin Oncol. 2010 Oct 20; 28(30):4630-4. Epub 2010 Jul 19.
Review Emerging trends in the clinical use of bortezomib in multiple myeloma. [Clin Lymphoma Myeloma. 2005]
Review Emerging trends in the clinical use of bortezomib in multiple myeloma.
Richardson PG, Schlossman R, Mitsiades C, Hideshima T, Munshi N, Anderson K. Clin Lymphoma Myeloma. 2005 Sep; 6(2):84-8.
Review Bortezomib: a review of its use in patients with multiple myeloma. [Drugs. 2009]
Review Bortezomib: a review of its use in patients with multiple myeloma.
Curran MP, McKeage K. Drugs. 2009; 69(7):859-88.

See reviews... See all...

Cited by 16 PubMed Central articles

Induction chemotherapy before autologous stem cell transplantation for symptomatic plasma cell myeloma - does it matter? [Clin Pharmacol. 2010]
Induction chemotherapy before autologous stem cell transplantation for symptomatic plasma cell myeloma - does it matter?
Fung HC, Nathan S, Maciejewski JJ. Clin Pharmacol. 2010; 2:71-5. Epub 2010 Apr 14.
Bortezomib in the management of multiple myeloma. [Cancer Manag Res. 2009]
Bortezomib in the management of multiple myeloma.
Laubach JP, Mitsiades CS, Hideshima T, Schlossman R, Chauhan D, Munshi N, Ghobrial I, Carreau N, Anderson KC, Richardson PG. Cancer Manag Res. 2009 Sep 8; 1:107-17. Epub 2009 Sep 8.
Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial. [Leukemia. 2010]
Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial.
Dispenzieri A, Jacobus S, Vesole DH, Callandar N, Fonseca R, Greipp PR. Leukemia. 2010 Aug; 24(8):1406-11. Epub 2010 Jun 10.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 del...
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials.
Leukemia. 2007 Jan ;21(1):151-7. Epub 2006 Nov 9 .

PubMed
Descemet membrane automated endothelial keratoplasty: hybrid technique combining...
Descemet membrane automated endothelial keratoplasty: hybrid technique combining DSAEK stability with DMEK visual results.
J Cataract Refract Surg. 2009 Oct ;35(10):1659-64.

PubMed
Downregulation of vertebrate Tel (ETV6) and Drosophila Yan is facilitated by an ...
Downregulation of vertebrate Tel (ETV6) and Drosophila Yan is facilitated by an evolutionarily conserved mechanism of F-box-mediated ubiquitination.
Mol Cell Biol. 2008 Jul ;28(13):4394-406. Epub 2008 Apr 21 .

PubMed
Crotalidae polyvalent immune Fab (ovine) antivenom is efficacious for envenomati...
Crotalidae polyvalent immune Fab (ovine) antivenom is efficacious for envenomations by Southern Pacific rattlesnakes (Crotalus helleri).
Ann Emerg Med. 2002 Dec ;40(6):619-24.

PubMed
Smoking as a precipitating factor for migraine: a survey in medical students.
Smoking as a precipitating factor for migraine: a survey in medical students.
J Headache Pain. 2009 Apr ;10(2):101-3. Epub 2009 Jan 31 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to:

Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Supplemental Content

Related citations

Cited by 16 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information